MOLECULAR INFECTIOUS DISEASE TESTING
PLEASE NOTE: EFFECTIVE APRIL 1, 2018 4PATH WILL NOW LONGER PROVIDING RESP-20 TESTING BASED ON THE BIO-FIRE PLATFORM FOR IT’S CLIENTS. OTHER RESPIRATORY TESTING TESTS AND PANELS ARE AVAILABLE UTILIZING OTHER MOLECULAR TESTING PLATFORMS. FOR MORE INFORMATION, PLEASE CONTACT LABORATORY TO ARRANGE FOR A REPRESENTATIVE TO PROVIDE YOU WITH ADDITIONAL INFORMATION.
4path is proud to announce that it now is providing rapid FDA approved Molecular Infectious Disease testing for our clients. These FDA approved tests provide rapid results utilizing RT-PCR molecular based testing procedures, ensuring a high degree of specificity and sensitivity.
GI-22, a FDA approved rt-PCR based infectious disease panel for 22 of the most common GI viral, bacterial and protozoan pathogens.
Please click on the appropriate panel to take you to full test descriptions, performance characteristics and other important information
Each individually packaged collection kit contains the materials necessary to collect the patient specimen, including full packaging and, where applicable, FedEx pre-paid mailer.
Contact 4path today at 1-877-884-7284 to start offering this important diagnostic aid to your practice.
Interested in learning more about the clinical use of the GI pathogen panel in your practice? Listen to this recent webinar.
How Syndromic Testing Can Improve Patient Care
The Impact of the Gastrointestinal Panel (Webinar)
4path’s GI-22 Infectious Diarrhea Profile
Infectious enteritis and foodborne infectious disease result in more the 300,000 emergency room visits annually, with an associated 225,000 inpatient admissions. The total cost of this? $1.8 BILLION dollars annually.
Unfortunately current “standard” diagnostics often don’t provide a definitive diagnosis in over 80% of cases. The majority of foodborne infectious disease is due to norovirus, however many laboratories are not equipped to make this diagnosis in a timely fashion…or at all.
Treatment decisions for infectious diarrhea often can change based on the infectious agent identified. For that reason, sensitive, specific and speedy (three “S”s) diagnoses are essential. Only molecular diagnostic methods can provide these benefits, allowing them to rapidly and specifically divide patients into the following categories:
- No infection
- Self limited diseases
- Virulent infections
Having this information can help treat patients more specifically and quickly resulting in:
- More specific treatment for the specific diagnosis
- Elimination of the use of antibiotics where not indicated, eliminating the risk to the patient of antibiotic related side effects or complications
- Appropriate triage of patients to proper health care settings based on the severity of the disease.
- Reduction of cost for the patient and impact on the health care system
- Better patient outcome and satisfaction